Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The trial, conducted in collaboration with the Swiss Group for Clinical Cancer Research (SAKK), will assess the safety, tolerability and anti-tumor activity of IP-001 administered intratumorally following tumor ablation.
Lead Product(s): N-dihydrogalactochitosan
Therapeutic Area: Oncology Product Name: IP-001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Swiss Group for Clinical Cancer Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020